miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation
Metrics: PDF 2489 views | HTML 2835 views | ?
Zhi-Jian Zou1,2, Lei Fan1, Li Wang1, Ji Xu1, Run Zhang1, Tian Tian1, Jian-Yong Li1 and Wei Xu1
1 Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
2 Department of Hematology, Wuxi People Hospital Affiliated of Nanjing Medical University, Wuxi, China
Wei Xu, email:
Keywords: chronic lymphocytic leukemia; PTEN; mutation; microRNA
Received: July 28, 2014 Accepted: October 23, 2014 Published: October 24, 2014
We previous found the expression level of PTEN was low in the chronic lymphocytic leukemia (CLL) patients. To assess the pathogenic contribution of the low expression of PTEN, we determined PTEN-regulating miRNA interference, PTEN promoter methylation and PTEN gene mutation condition in CLL.
One hundred and fifty-four previously untreated CLL patients and 200 cases of healthy controls were sequenced in exons 5−9 of PTEN. None of single nucleotide polymorphism site or mutation was detected in the coding sequences of those exons. Methylation of PTEN promoter was found in one (1.33%) of the 75 patients with CLL, but none of the 25 age-matched control subjects. We found that PTEN was a potential target of miR-26a and miR-214, which had been confirmed following dual-luciferase reporter assays, reverse transcription polymerase chain reaction and Western blotting. High expression of miR-26a was associated with advanced Binet stage (P=0.012), p53 aberrations (P=0.014) and inferior time to first treatment (P=0.038), and high expression of miR-214 was only associated with p53 aberrations (P=0.041). Inhibition of miR-26a or miR-214 could induce more apoptosis in primary cultured CLL cells. These findings support miR-26a and miR-214 down-regulate expression of PTEN in CLL, but not PTEN mutation or promoter methylation.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.